TARBP2

Across TCGA pan-cancer cohorts, TARBP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TARBP2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TARBP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TARBP2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

HNSC, LSCC, and CCRCC are the cancer types where TARBP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.689	0.866	.004	50	view →
LSCC	DFS	Quartile	II,III,IV	0.896	0.404	<.001	33	view →
CCRCC	DFS	Tertile	All	0.573	0.852	.002	29	view →
LUAD	DFS	Quartile	All	0.474	0.752	.028	3	view →
PDAC	OS	Tertile	All	0.456	0.687	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TARBP2–HNSC (DFS)

Open the HNSC breakdown →